

CITATION REPORT

List of articles citing

Changes in glitazone use among office-based physicians in the U.S., 2003-2009

DOI: 10.2337/dc09-1834
Diabetes Care, 2010, 33, 823-5.

Source: <https://exaly.com/paper-pdf/49067651/citation-report.pdf>

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
45	Solubility of pioglitazone hydrochloride in binary and ternary mixtures of water, propylene glycol, and polyethylene glycols 200, 400, and 600 at 298.2K. <i>AAPS PharmSciTech</i> , 2010 , 11, 1713-7	3.9	12
44	Current literature in diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2010 , 26, i-x	7.5	
43	Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. <i>Diabetes Care</i> , 2011 , 34, 1369-71	14.6	184
42	Antidiabetic prescribing trends and predictors of thiazolidinedione discontinuation following the 2007 rosiglitazone safety alert. <i>Diabetes Research and Clinical Practice</i> , 2011 , 93, 49-55	7.4	21
41	Drug vs class-specific black box warnings: does one bad drug spoil the bunch?. <i>Journal of General Internal Medicine</i> , 2011 , 26, 570-2	4	2
40	POTENTIALLY DANGEROUS SIDE-EFFECTS OF DRUGS AND BLACK BOX WARNING SYSTEM. <i>Acta Medica Medianae</i> , 2011 , 69-73	0	
39	State Medicaid programs did not make use of prior authorization to promote safer prescribing after rosiglitazone warning. <i>Health Affairs</i> , 2012 , 31, 188-98	7	12
38	Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review. <i>Medical Care</i> , 2012 , 50, 466-78	3.1	163
37	Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system database. <i>Drug Safety</i> , 2012 , 35, 315-23	5.1	29
36	Prescribing of rosiglitazone and pioglitazone following safety signals: analysis of trends in dispensing patterns in the Netherlands from 1998 to 2008. <i>Drug Safety</i> , 2012 , 35, 471-80	5.1	32
35	Thiazolidinedione drugs promote onset, alter characteristics, and increase mortality of ischemic ventricular fibrillation in pigs. <i>Cardiovascular Drugs and Therapy</i> , 2012 , 26, 195-204	3.9	11
34	Rosiglitazone use and associated adverse event rates in Canada between 2004 and 2010. <i>BMC Research Notes</i> , 2013 , 6, 82	2.3	8
33	Fucosylated chondroitin sulfate from <i>Acaudina molpadioides</i> improves hyperglycemia via activation of PKB/GLUT4 signaling in skeletal muscle of insulin resistant mice. <i>Food and Function</i> , 2013 , 4, 1639-46	6.1	42
32	Fucosylated chondroitin sulfate from sea cucumber in combination with rosiglitazone improved glucose metabolism in the liver of the insulin-resistant mice. <i>Bioscience, Biotechnology and Biochemistry</i> , 2013 , 77, 2263-8	2.1	31
31	Limitations and potential misinterpretation of the National Disease and Therapeutic Index. <i>International Journal of Pharmaceutical and Healthcare Marketing</i> , 2013 , 7, 34-44	1.3	1
30	Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012. <i>Diabetes Care</i> , 2014 , 37, 985-92	14.6	101
29	Fucosylated chondroitin sulfate from sea cucumber improves glucose metabolism and activates insulin signaling in the liver of insulin-resistant mice. <i>Journal of Medicinal Food</i> , 2014 , 17, 749-57	2.8	28

28	Retrospective review of superficial femoral artery stenting in diabetic patients: thiazolidinedione use may decrease reinterventions. <i>BMC Cardiovascular Disorders</i> , 2014 , 14, 184	2.3	1
27	Use of antidiabetic drugs in the U.S., 2003-2012. <i>Diabetes Care</i> , 2014 , 37, 1367-74	14.6	152
26	Fucoidan from sea cucumber protects against high-fat high-sucrose diet-induced hyperglycaemia and insulin resistance in mice. <i>Journal of Functional Foods</i> , 2014 , 10, 128-138	5.1	53
25	Changes in prescribing patterns and clinical outcomes in elderly diabetic patients in 2000 and 2010: analysis of a large Italian population-based study. <i>European Journal of Clinical Pharmacology</i> , 2014 , 70, 965-74	2.8	6
24	The skeletal effects of pioglitazone in type 2 diabetes or impaired glucose tolerance: a randomized controlled trial. <i>European Journal of Endocrinology</i> , 2014 , 170, 255-62	6.5	32
23	Utilisation trends of rosiglitazone and pioglitazone in Australia before and after safety warnings. <i>BMC Health Services Research</i> , 2014 , 14, 151	2.9	12
22	Effects of safety warnings and risk management plan for Thiazolidinediones in Taiwan. <i>Pharmacoepidemiology and Drug Safety</i> , 2015 , 24, 1026-35	2.6	7
21	Geographic Variation in Rosiglitazone Use Surrounding FDA Warnings in the Department of Veterans Affairs. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2015 , 21, 1214-34	1.9	4
20	Trends in Antihyperglycemic Medication Prescriptions and Hypoglycemia in Older Adults: 2002-2013. <i>PLoS ONE</i> , 2015 , 10, e0137596	3.7	32
19	How Did Multiple FDA Actions Affect the Utilization and Reimbursed Costs of Thiazolidinediones in US Medicaid?. <i>Clinical Therapeutics</i> , 2015 , 37, 1420-1432.e1	3.5	7
18	Impact of rosiglitazone safety alerts on oral antidiabetic sales trends: a countrywide study in Portugal. <i>Fundamental and Clinical Pharmacology</i> , 2016 , 30, 440-9	3.1	6
17	Medication usage, treatment intensification, and medical cost in patients with type 2 diabetes: a retrospective database study. <i>BMJ Open Diabetes Research and Care</i> , 2016 , 4, e000189	4.5	12
16	Novel Therapeutics for Diabetes: Uptake, Usage Trends, and Comparative Effectiveness. <i>Current Diabetes Reports</i> , 2016 , 16, 47	5.6	16
15	New Initiation of Long-Acting Opioids in Long-Stay Nursing Home Residents. <i>Journal of the American Geriatrics Society</i> , 2016 , 64, 1772-8	5.6	10
14	Drug safety and the impact of drug warnings: An interrupted time series analysis of diabetes drug prescriptions in Germany and Denmark. <i>Health Policy</i> , 2016 , 120, 1404-1411	3.2	3
13	Influence of health warnings on the use of rosiglitazone and pioglitazone in an area of Spain: A time-series study. <i>SAGE Open Medicine</i> , 2016 , 4, 2050312116653054	2.4	3
12	Drug safety: withdrawn medications are only part of the picture. <i>BMC Medicine</i> , 2016 , 14, 28	11.4	8
11	Changes in prescribing and healthcare resource utilization after FDA Drug Safety Communications involving zolpidem-containing medications. <i>Pharmacoepidemiology and Drug Safety</i> , 2017 , 26, 712-721	2.6	25

10	T-cell Metabolism as a Target to Control Autoreactive T Cells in ECell Autoimmunity. <i>Current Diabetes Reports</i> , 2017 , 17, 24	5.6	6
9	The impact of FDA regulatory activities on incident dispensing of LABA-containing medication: 2005-2011. <i>Journal of Asthma</i> , 2018 , 55, 907-914	1.9	1
8	Changes in the utilization of osteoporosis drugs after the 2010 FDA bisphosphonate drug safety communication. <i>Saudi Pharmaceutical Journal</i> , 2018 , 26, 238-243	4.4	11
7	Measuring the impact of medicines regulatory interventions - Systematic review and methodological considerations. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 419-433	3.8	45
6	Unintended Effects of Communicating About Drug Safety Issues: A Critical Review of the Literature. <i>Drug Safety</i> , 2019 , 42, 1125-1134	5.1	5
5	Implications of Removing Rosiglitazone's Black Box Warning and Restricted Access Program on the Uptake of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors Among Patients with Type 2 Diabetes. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2019 , 25, 72-79	1.9	8
4	A Practical Approach to Mental Health for the Diabetes Educator. <i>AADE in Practice</i> , 2019 , 7, 29-44	0.3	17
3	Ambulatory noninsulin treatment of type 2 diabetes mellitus in the United States, 2015 to 2019. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1843-1850	6.7	4
2	The Actions of PPAR α Agonists on the Various Target Organs. <i>The Korean Journal of Obesity</i> , 2011 , 20, 161		2
1	Ambulatory Fluoroquinolone Use in the United States, 2015-2019.. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab538	1	1